Activity of the medial prefrontal cortex and amygdala underlies one-trial tolerance of rats in the elevated plus-maze.
The anxiolytic effects of benzodiazepines are reduced after a single exposure of rats to elevated plus-maze test (EPM). Midazolam showed an anxioselective profile in animals submitted to one session (T1) but did not change the usual exploratory behavior of rats exposed twice (T2) to the EPM. In this study we examined further the one-trial tolerance by performing a factor analysis of the exploratory behavior of rats injected with saline before both trials as well as an immunohistochemistry study for quantification of Fos expression in encephalic structures after these sessions. Factor analysis of all behavioral categories revealed that factor 1 consisted of anxiety-related categories in T1 whereas these same behavioral categories loaded on factor 2 in T2. Risk assessment was also dissociated as it loaded stronger on T2 (factor 3) than on T1 (factor 4). Locomotor activity in T1 loaded on factor 5. Immunohistochemistry analyses showed that Fos expression predominated in limbic structures in T1 group. The medial prefrontal cortex and amygdala were the main areas activated in T2 group. These data suggest that anxiety and risk assessment behaviors change their valence across the EPM sessions. T2 is characterized by the emergence of a fear factor, more powerful risk assessment and medial prefrontal cortex activation. The amygdala functions as a switch between the anxiety-like patterns of T1 to the cognitive control of fear prevalent in T2. The EPM retest session is proposed as a tool for assessing the cognitive activity of rodents in the control of fear.
Albrechet-Souza
Lucas
L
Instituto de Neurociências & Comportamento-INeC, Campus USP, Av. Bandeirantes 3900, 14049-901 Ribeirão Preto, São Paulo, Brazil.
Borelli
Karina G
KG
Brandão
Marcus L
ML
D000679:Amygdala / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D001008:Anxiety Disorders / Q000188:drug therapy / Q000503:physiopathology; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D001931:Brain Mapping; D003071:Cognition / Q000187:drug effects / Q000502:physiology; D004361:Drug Tolerance / Q000502:physiology*; D005239:Fear / Q000187:drug effects / Q000502:physiology; D007150:Immunohistochemistry; D008032:Limbic System / Q000187:drug effects / Q000502:physiology; D008297:Male; D018782:Maze Learning / Q000187:drug effects* / Q000502:physiology; D008874:Midazolam / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009480:Neuropharmacology / Q000379:methods*; D009483:Neuropsychological Tests; D017397:Prefrontal Cortex / Q000187:drug effects / Q000502:physiology*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
D014151:Anti-Anxiety Agents; D016760:Proto-Oncogene Proteins c-fos; D008874:Midazolam